検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1292 : RBE  update : 2024/04/11
細胞特性(Comment:英)Human intrahepatic cholangiocarcinoma.Please read carefully this information before use.
細胞特性(日)ヒト肝内胆管癌細胞株。必ずお読みください。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Enjoji, Munechika
樹立者 Enjoji, Munechika
寄託日 1996
動物種 _human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Female
採取組織 liver
病名 cholangiocarcinoma
細胞分類 cancer
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_4896
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培地 RPMI1640 + 10% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : once/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
ウィルス(HBV) (-)
ウィルス(HCV) (-)
アイソザイム検査 LD, NP
染色体検査 77-87(50) : 77(6),78(7),79(7),80(7),81(5),82(5)/
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 0件
Reference(日) 0件
利用者成果(英) 66件
利用者成果(日) 0件

トップへページトップへ
Reference(英)

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
21103  Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N.  SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.  Nat Cancer  2023    PubMed ID: 36914816   DOI: 10.1038/s43018-023-00523-0
21205  Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V.  Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04).  Clin Cancer Res  2023    PubMed ID: 37115501   DOI: 10.1158/1078-0432.CCR-23-0036
21324  Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK.  Molecular profiling reveals potential targets in cholangiocarcinoma.  World J Gastroenterol  2023  29(25):4053-4071  PubMed ID: 37476584   DOI: 10.3748/wjg.v29.i25.4053
21390  Chen CP, Yeh CN, Pan YR, Huang WK, Hsiao YT, Lo CH, Wu CE.  Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer.  Biomed Pharmacother  2023  166:115389  PubMed ID: 37659202   DOI: 10.1016/j.biopha.2023.115389
21500  Pan YR, Lai JC, Huang WK, Peng PH, Jung SM, Lin SH, Chen CP, Wu CE, Hung TH, Yu AL, Wu KJ, Yeh CN.  PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions.  Cancer Gene Ther  2023    PubMed ID: 38057358   DOI: 10.1038/s41417-023-00705-z
17553  Koike K, Masuda T, Sato K, Fujii A, Wakiyama H, Tobo T, Takahashi J, Motomura Y, Nakano T, Saito H, Matsumoto Y, Otsu H, Takeishi K, Yonemura Y, Mimori K, Nakagawa T.  GET4 is a novel driver gene in colorectal cancer that regulates the localization of BAG6, a nucleocytoplasmic shuttling protein  Cancer Sci  2022  113(1):156-169  PubMed ID: 34704338   DOI: 10.1111/cas.15174
17715  Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z.  Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance  Front Oncol  2022  12:871281  PubMed ID: 35965521   DOI: 10.3389/fonc.2022.871281
18223  Mancarella S, Serino G, Gigante I, Cigliano A, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G.  CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype  J Exp Clin Cancer Res  2022  41(1):65  PubMed ID: 35172861   DOI: 10.1186/s13046-022-02283-8
20420  Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC.  Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.  Hepatol Commun  2022    PubMed ID: 34558800   DOI: 10.1002/hep4.1682
20697  Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K.  Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.  Toxicol In Vitro  2022  105385  PubMed ID: 35568131   DOI: 10.1016/j.tiv.2022.105385
20723  Satow R, Aiga Y, Watanabe T, Ishizuka N, Yoneda A, Fukami K.  Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells.  Biochem Biophys Rep  2022  31:101289  PubMed ID: 35669984   DOI: 10.1016/j.bbrep.2022.101289
20763  Tanaka R, Kimura K, Eguchi S, Ohira G, Tanaka S, Amano R, Tanaka H, Yashiro M, Ohira M, Kubo S.  Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line.  BMC Cancer  2022  22(1):748  PubMed ID: 35804329   DOI: 10.1186/s12885-022-09847-z
20772  Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T.  KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression.  Liver Int  2022    PubMed ID: 35833881   DOI: 10.1111/liv.15366
20794  Chen S, Nishi M, Morine Y, Yoshikawa K, Tokunaga T, Kashihara H, Takasu C, Wada Y, Yoshimoto T, Nakamoto A, Sakai T, Shimada M.  Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts.  Oncol Lett  2022  24(1):236  PubMed ID: 35720469   DOI: 10.3892/ol.2022.13356
20925  Wu CE, Chen CP, Pan YR, Jung SM, Chang JW, Chen JS, Yeh CN, Lunec J.  In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.  Am J Cancer Res  2022  12(9):4399-4410  PubMed ID: 36225643  
13539  Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.  Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis  Dig Dis Sci  2021  66(4):1080-1089  PubMed ID: 32445050   DOI: 10.1007/s10620-020-06330-2
15516  Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T.  Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma  ancers (Basel)   2021  13(11):2804  PubMed ID: 34199886   DOI: 10.3390/cancers13112804
16118  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M  Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth  FEBS Open Bio  2021  11(12):3276-329  PubMed ID: 34510808   DOI: 10.1002/2211-5463.13294
12038  Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Shirabe K.  Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.  Br. J. Cancer  2020    PubMed ID: 32015511   DOI: 10.1038/s41416-020-0744-7
12462  Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.  Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma  Carcinogenesis  2020  41(6):734-742  PubMed ID: 31665232   DOI: 10.1093/carcin/bgz179
13005  Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y.  TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma.  Cancers (Basel)  2020    PubMed ID: 32365487   DOI: 10.3390/cancers12051105
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492   DOI: 10.3390/biom10111529
13579  Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer  Cancer Chemother Pharmacol  2020  85(6):1063-1078  PubMed ID: 32440762   DOI: 10.1007/s00280-020-04079-z
13917  Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Miura K, Mizuma M, Unno M, Kawamura S, Sato I, Yasuda J, Yamaguchi K,   BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma  Sci Rep  2020  10(1):21592  PubMed ID: 33299012   DOI: 10.1038/s41598-020-78539-0
16133  Fu W, Yu G, Liang J, Fan P, Dong K, Zhang B, Chen X, Zhu H, Chu L.  miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4  Front Oncol  2020  10:563486  PubMed ID: 33520692   DOI: 10.3389/fonc.2020.563486
11443  Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.  Invest New Drugs  2019    PubMed ID: 30778887   DOI: 10.1007/s10637-019-00741-3
14816  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma  Cancer Discov  2019  9(8):1064-1079  PubMed ID: 31109923   DOI: 10.1158/2159-8290.CD-19-0182
10658  Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.  Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.  Oncol. Rep.  2018  39:843-850  PubMed ID: 29251327   DOI: 10.3892/or.2017.6153
10816  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.  Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.  Oncotarget  2018  9:16400-16417  PubMed ID: 29662654   DOI: 10.18632/oncotarget.24711
11206  Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, Katayama H, Ogiso S, Fukumitsu K, Uemoto S.  CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis.  J Surg Oncol  2018    PubMed ID: 30196535   DOI: 10.1002/jso.25192
4337  Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, Kaida T, Arima K, Kitano Y, Kuroki H, Mima K, Nitta H, Imai K, Hashimoto D, Yamashita YI, Chikamoto A, Baba H.  Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.  HPB (Oxford)  2018    PubMed ID: 29759640   DOI: 10.1016/j.hpb.2018.03.018
4338  Fujiwara H, Tateishi K, Kato H, Nakatsuka T, Yamamoto K, Tanaka Y, Ijichi H, Takahara N, Mizuno S, Kogure H, Matsubara S, Nakai Y, Koike K.  Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.  Cancer Sci.  2018    PubMed ID: 30156013   DOI: 10.1111/cas.13784
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867   DOI: 10.1111/cas.13829
4486  Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.  Hepatology  2018  68(3):949-963  PubMed ID: 29278425   DOI: 10.1002/hep.29764
5802  Eguchi T et al  Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.  PLoS One  2018  13(2):e0191109.  PubMed ID: 29415026   DOI: 10.1371/journal.pone.0191109
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
14942  Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X.  Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice  Oncogene  2018  ;37(24):3229-3242  PubMed ID: 29545603   DOI: 10.1038/s41388-018-0188-1
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612   DOI: 10.1002/mc.22671
10333  Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT.  CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.  BMC Cancer  2017  17:395  PubMed ID: 28576144   DOI: 10.1186/s12885-017-3389-z
10501  Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S.  5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice.  In Vivo  2017  31:905-908  PubMed ID: 28882957   DOI: 10.21873/invivo.11145
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14528  Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.  Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree  PLoS One  2017  12(4):e0175355  PubMed ID: 28388653   DOI: 10.1371/journal.pone.0175355
9923  Aoki S, Mizuma M, Takahashi Y, Haji Y, Okada R, Abe T, Karasawa H, Tamai K, Okada T, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Katayose Y, Unno M.  Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.  BMC Cancer  2016  16:854  PubMed ID: 27821106   DOI: 10.1186/s12885-016-2919-4
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
12878  Yang SH, Lin HY, Changou CA, Chen CH, Liu YR, Wang J, Jiang X, Luh F, Yen Y.  Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma  Oncotarget  2016  7(1):362-73  PubMed ID: 26517522   DOI: 10.18632/oncotarget.6238
5025  Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H.  Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.  Cancer Sci  2015  106(9):1153-62  PubMed ID: 26132727   DOI: 10.1111/cas.12732
15203  Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y.  Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma  Oncotarget  2015  6(22):18905-20  PubMed ID: 26056085   DOI: 10.18632/oncotarget.4305
14098  Liu TT, You HL, Weng SW, Wei YC, Eng HL, Huang WT.  Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma  PLoS One  2015  10(12):e0145388  PubMed ID: 26684807   DOI: 10.1371/journal.pone.0145388
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196   DOI: 10.1111/hepr.12312
14393  Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H.  Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells  Oncol Rep  2014  31(2):983-8  PubMed ID: 24337160   DOI: 10.3892/or.2013.2922
16018  Jachin S, Bae JS, Sung JJ, Park HS, Jang KY, Chung MJ, Kim DG, Moon WS.  The role of nuclear EpICD in extrahepatic cholangiocarcinoma: association with β-catenin  Int J Oncol   2014  45(2):691-8  PubMed ID: 24888903   DOI: 10.3892/ijo.2014.2472
18681  Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM.  A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma  Hum Gene Ther  2013  24(5):554-64  PubMed ID: 23550539   DOI: 10.1089/hum.2012.136
12544  Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.  Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma  Hepatol Res  2013  43(9):959-69  PubMed ID: 23369163   DOI: 10.1111/hepr.12047
16575  Jamiyandorj U, Bae JS, Noh SJ, Jachin S, Choi JE, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS.  Expression of peptidyl-prolyl isomerase PIN1 and its role in the pathogenesis of extrahepatic cholangiocarcinoma  Oncol Lett  2013  6(5):1421-1426  PubMed ID: 24179535   DOI: 10.3892/ol.2013.1525
17161  Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B, Chen X.  JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner  Mol Med Rep  2013  8(6):1623-9  PubMed ID: 24100678   DOI: 10.3892/mmr.2013.1711
5863  Yoshii Y, Waki A, Yoshida K, Kakezuka A, Kobayashi M, Namiki H, Kuroda Y, Kiyono Y, Yoshii H, Furukawa T, Asai T, Okazawa H, Gelovani JG, Fujibayashi Y.  The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation.  Biomaterials  2011  32(26):6052-8  PubMed ID: 21640378   DOI: 10.1016/j.biomaterials.2011.04.076
8365  Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S.  Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma.  Cancer Lett.  2010  294:25-34  PubMed ID: 20149523   DOI: 10.1016/j.canlet.2010.01.019
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
12770  Xu HL, Inagaki Y, Seyama Y, Sugawara Y, Kokudo N, Nakata M, Wang FS, Tang W.  Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion  Life Sci  2009  85(9-10):395-400  PubMed ID: 19631667   DOI: 10.1016/j.lfs.2009.07.004
18314  Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M.  Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma  J Hepatol  2008  49(5):746-57.  PubMed ID: 18752864   DOI: 10.1016/j.jhep.2008.06.019
18693  Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.  Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer  Gastroenterology  2008  135(4):1358-1368  PubMed ID: 18692501   DOI: 10.1053/j.gastro.2008.06.082
3575  Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T.  Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.  Hepatology  2008  47(3):888-96  PubMed ID: 18306229   DOI: 10.1002/hep.22125
3077  Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.  Mol Cancer Ther  2005  4:399-412  PubMed ID: 15767549   DOI: 10.1158/1535-7163.MCT-04-0234
3334  Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi  Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma  Oncol Res  2005  14:701-706  PubMed ID: 16077978  
3346  Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo  Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells.  Hepatology  2004  40:609-17  PubMed ID: 15349899   DOI: 10.1002/hep.20372
3703  Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J.  Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers.  Cancer Sci  2004  95(12):969-76  PubMed ID: 15596046   DOI: 10.1111/j.1349-7006.2004.tb03185.x

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ